Columbia Launches Research Stabilization Funds After Trump Cuts
Columbia University has launched two research stabilization funds after US President Donald Trump pulled $400 million from its funding, according to a post on its website written by the school's Acting President Claire Shipman.
The first fund, created with the support of NewYork-Presbyterian Hospital, is focused on clinical and translational research from the Vagelos College of Physicians and Surgeons. The second one supports researchers more broadly, particularly graduate students and postdoctoral fellows whose grants have been affected.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Lilly's experimental obesity drug shows promise in early study
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the obesity market. The drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months, according to an abstract posted Friday ahead of the American Diabetes Association conference in Chicago. The drug is moving to the next stage of development and researchers will present details on dosing and safety at the conference next week. "The data look particularly strong, and should push the program back into investor conversations," Cantor Fitzgerald analyst Prakhar Agrawal wrote in a note to investors. Lilly has shared few details about eloralintide before now, as it's still in the early stages of testing. It's part of a class of drugs that mimic the hormone amylin, which slows digestion and makes people feel full longer. They're thought to be a gentler option for losing weight than currently available injections like Zepbound and Wegovy, which often have side effects like nausea and vomiting. The study enrolled 100 patients who were given different doses of the experimental drug or a placebo for 12 weeks. Weight loss ranged from 2.6% to 11.3%, according to the abstract. Gastrointestinal side effects were relatively minimal, with about 10% of patients experiencing diarrhea and 8% vomiting. Few details were provided, however, including information on risks and benefits based on dose. The promise of drugs that are easier to take than blockbusters like Lilly's Zepbound and its rival Wegovy, from Novo Nordisk A/S, has drawn increasing interest from companies hoping for a piece of pharma's hottest market. In March, Roche Holding AG entered into a $5.3 billion deal to co-develop and commercialize Zealand Pharma A/S' amylin drug, called petrelintide. It is seen as the one to beat in the amylin class, with early trials showing patients lost as much as 8.6% of their body weight in four months, with less nausea than Lilly and Novo's current therapies. AbbVie Inc. agreed to pay as much as $2.2 billion in March for an amylin drug from Danish biotech Gubra A/S, marking its first foray into the obesity market. New York-based startup Metsera Inc. is developing a related compound that may be taken less frequently than weekly shots like Zepbound and Wegovy. Lilly is already a leader in the obesity market, where Zepbound is capturing the majority of new prescriptions. The company has several promising next-generation products in the late stages of development, including a pill called orforglipron and an experimental shot that's thought to be even more effective for weight loss. The company is studying eloralintide alone and in combination with Zepbound - similar to the approach Novo is taking with its next-generation drug CagriSema, which combines an amylin component with semaglutide, the backbone of Wegovy and the diabetes drug Ozempic. Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Associated Press
an hour ago
- Associated Press
US Lab Partners and SciSure Launch Strategic Partnership to Transform EHS Services and Lab Operations
BOSTON MA - SciSure, the Scientific Management Platform (SMP) designed to unify scientific research, safety, operations, and compliance, today announced a strategic partnership with US Lab Partners, a leader in lab and facility operations and EHS (Environmental Health & Safety) consulting. Together, the organizations are launching a transformative 'Virtual Incubator Model' that gives emerging and scaling life science organizations affordable access to world-class digital lab infrastructure and operational support. Unlocking Modern Lab Management for Scientific Entrepreneurs Emerging life science organizations have long faced a costly challenge: accessing high-quality EHS, lab operations, and compliance infrastructure before they have the resources or scale to support large software investments. The new SciSure and US Lab Partners collaboration eliminates this barrier. By combining SciSure's comprehensive, scalable software suite with US Lab Partners' expert consulting and implementation services, these organizations can now operate efficient, safe, and compliant labs from day one. 'Our customers have often told us they needed digital infrastructure long before they had the budget or internal resources to manage it,' said Philip Meer, CEO of SciSure. 'This partnership ensures they no longer have to choose between premium software or on-the-ground expert services - they get both, seamlessly integrated.' Better Together: A Complete Solution for Emerging Labs US Lab Partners provides deep, hands-on expertise in lab setup, operations, and EHS compliance. They become an extension of the customer's internal team, guiding labs through complex requirements and day-to-day operations. SciSure complements this with an industry-leading platform encompassing Electronic Lab Notebooks (ELN), Laboratory Information Management Systems (LIMS), inventory tracking and EHS workflows, all in one secure and scalable environment. 'Too often, emerging scientific companies are forced to rely on underpowered tools, systems that create data silos and are little more than glorified spreadsheets,' said Jon Zibell, Vice President of Global Alliances and Marketing at SciSure. 'This partnership is designed to change that. We are delivering a seamless digital experience from day one, without sacrificing safety, compliance, or data integrity.' 'Digitizing lab operations is no longer optional - it's critical for continuity, safety, and scientific integrity,' said Demet Aybar, CEO and Founder of US Lab Partners. 'Together with SciSure, we're delivering world-class software and hands-on expertise that have traditionally been reserved for Big Pharma, now accessible to startups and academic innovators.' Impacting the Future of Scientific Innovation This partnership marks a pivotal shift in how scientific organizations can launch and operate. By eliminating the traditional burden of high costs, fragmented systems, and lack of technical resources, the Virtual Incubator Model accelerates innovation while reducing overhead and risk. Customers now gain access to a fully digital and seamlessly integrated record-keeping system from day one, end-to-end EHS and inventory management software and services, a robust LMS with training content library, tusted partners who bring both software and service to manage lab setup, safety, and compliance, as well as ELN, LIMS, SOP's, and Sample Management built-in. 'This model reflects our shared mission: to help brilliant science thrive without operational bottlenecks,' Aybar added. 'We're here to make world-class lab infrastructure available without compromise.' Media Contact Company Name: SciSure Contact Person: Anne-Marie Miscioscia Email: Send Email Country: United States Website: Source: PR Company
Associated Press
an hour ago
- Associated Press
Notification of Data Security Incident
LAS VEGAS, June 13, 2025 /PRNewswire/ -- Effortless Office Enterprises, LLC ('Effortless Office') has learned of a data security incident that may have involved personal and/or protected health information of certain employees and patients of Nevada Heart and Vascular ('NHV'). Notice of this incident has been sent to certain affected current/former employees, patients, and/or associated parties and provided resources to assist them. Upon learning of suspicious activity temporarily within its computer network, Effortless Office promptly took steps to secure the environment and began an investigation to determine the nature and scope of the issue. In addition, they began working to restore impacted systems as quickly as possible and engaged digital forensics specialists to conduct an investigation. The investigation determined that unauthorized access occurred at certain times between May 9, 2024 and July 23, 2024. After determining that personal information may have been impacted, Effortless Office completed a comprehensive programmatic and manual review to identify what personal information was impacted and to whom it belonged. On May 12, 2025, Nevada Heart & Vascular Center, LLP learned that certain personal information was impacted in connection with the incident. The following information may have been affected as a result of the incident: Social Security number, taxpayer identification number, driver's license or state identification, passport number, date of birth, account number, routing number, security code, payment card number, payment card pin, payment card expiration date, health insurance information, medical information, and biometric data. On June 13, 2025, a notification letter was mailed to affected individuals, for whom address information was available. A toll-free call center has been established to answer questions about the incident and address related concerns. Call center representatives are available Monday through Friday from 9:00 am to 9:00 pm Eastern Time and can be reached at 1-855-200-7910. The privacy and protection of personal and protected health information is a top priority for Effortless Office, which deeply regrets any inconvenience or concern this incident may cause. View original content: SOURCE Effortless Office Enterprises, LLC
